Page 587 - Williams Hematology ( PDFDrive )

562 Part VI: The Erythrocyte <CN>: <CT> PB

35. Ogihara T, Katoh H, Yoshitake H, et al: Hyperthyroidism associated with autoimmune 68. Nakada D, Oguro H, Levi BP, et al: Oestrogen increases haematopoietic stem-cell
hemolytic anemia and periodic paralysis: A report of a case in which antihyperthyroid self-renewal in females and during pregnancy. Nature 505(7484):555–558, 2014.
therapy alone was effective against hemolysis. Jpn J Med 26(3):401–403, 1987. 69. Bates AS, Van’t Hoff W, Jones PJ, et al: The effect of hypopituitarism on life expectancy.
36. Lima CSP, Zantut Wittmann DE, Castro V, et al: Pancytopenia in untreated patients J Clin Endocrinol Metab 81(3):1169–1172, 1996.
with graves’ disease. Thyroid 16(4):403–409, 2006. 70. Greig HB, Metz J, Sunn L: Anaemia in hypopituitarism; treatment with testosterone
37. Akoum R, Michel S, Wafic T, et al: Myelodysplastic syndrome and pancytopenia and cortisone. S Afr J Lab Clin Med 2(1):52–61, 1956.
responding to treatment of hyperthyroidism: Peripheral blood and bone marrow anal- 71. Berlin NI, Van Dyke DC, Siri WE, et al: The effect of hypophysectomy on the total
ysis before and after antihormonal treatment. J Cancer Res Ther 3(1):43–46, 2007. circulating red cell volume of the rat. Endocrinology 47(6):429–435, 1950.
38. Baez-Villasenor J, Rath CE, Finch CA: The blood picture in Addison’s disease. Blood 72. Crafts RC, Meineke HA: The anemia of hypophysectomized animals. Ann N Y Acad Sci
3(7):769–773, 1948. 77:501–517, 1959.
39. Bozzini CE, Barrio Rendo ME, Kofoed JA, et al: Effect of hydrocortisone administra- 73. Van Dyke DC, Garcia JF, Simpson ME, et al: Maintenance of circulating red cell vol-
tion on erythropoiesis in the adrenalectomized dog. Experientia 24(8):800–801, 1968. ume in rats after removal of the posterior and intermediate lobes of the pituitary. Blood
40. Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syndromes. N Engl J Med 7(10):1005–1016, 1952.
350(20):2068–2079, 2004. 74. Crafts RC: The similarity between anemia induced by hypophysectomy and that
41. Toonkel R, Levine M, Gardner L: Erythropoietin-deficient anemia associated with induced by a combined thyroidectomy and adrenalectomy in adult female rats. Endo-
autoimmune polyglandular syndrome type I. Am J Hematol 75(2):84–88, 2004. crinology 53(5):465–473, 1953.
42. von Lindern M, Zauner W, Mellitzer G, et al: The glucocorticoid receptor cooperates 75. Ellegala DB, Alden TD, Couture DE, et al: Anemia, testosterone, and pituitary adenoma
with the erythropoietin receptor and c-kit to enhance and sustain proliferation of ery- in men. J Neurosurg 98(5):974–977, 2003.
throid progenitors in vitro. Blood 94(2):550–559, 1999. 76. Kim D-Y, Kim JH, Park YJ, et al: Case of complete recovery of pancytopenia after treat-
43. Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing’s syndrome. Am J ment of hypopituitarism. Ann Hematol 83(5):309–312, 2004.
Med 13(5):597–614, 1952. 77. Ferrari E, Ascari E, Bossolo PA, et al: Sheehan’s syndrome with complete bone mar-
44. Mann DL, Gallagher NI, Donati RM: Erythrocytosis and primary aldosteronism. Ann row aplasia: Long-term results of substitution therapy with hormones. Br J Haematol
Intern Med 66(2):335–340, 1967. 33(4):575–582, 1976.
45. Erkelens DW, Statius van Eps LW: Bartter’s syndrome and erythrocytosis. Am J Med 78. Nomiyama J, Shinohara K, Inoue H: Improvement of anemia by recombinant erythropoi-
55(5):711–719, 1973. etin in a patient with postoperative hypopituitarism. Am J Hematol 47(3):249–250, 1994.
46. Ambrogio AG, De Martin M, Ascoli P, et al: Gender-dependent changes in haemato- 79. Golde DW, Bersch N, Li CH: Growth hormone: Species-specific stimulation of erythro-
logical parameters in patients with Cushing’s disease before and after remission. Eur J poiesis in vitro. Science 196(4294):1112–1113, 1977.
Endocrinol 170(3):393–400, 2014. 80. Merchav S, Tatarsky I, Hochberg Z: Enhancement of erythropoiesis in vitro by human
47. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase defi- growth hormone is mediated by insulin-like growth factor I. Br J Haematol 70(3):
ciency. Endocr Rev 21(3):245–291, 2000. 267–271, 1988.
48. Albareda MM, Rodríguez-Espinosa J, Remacha A, et al: Polycythemia in a patient with 81. Eugster EA, Fisch M, Walvoord EC, et al: Low hemoglobin levels in children with in
21-hydroxylase deficiency. Haematologica 85 (E-letters):E08, 2000. idiopathic growth hormone deficiency. Endocrine 18(2):135–136, 2002.
49. Ramos I, Regadera A, Román P, et al: [Congenital adrenal hyperplasia owing to 82. Ten Have SM, van der Lely AJ, Lamberts SW: Increase in haemoglobin concentrations
21-hydroxylase deficiency presenting with erythrocytosis] [in Spanish]. Med Clin in growth hormone deficient adults during human recombinant growth hormone
(Barc) 131(16):638–639, 2008. replacement therapy. Clin Endocrinol (Oxf) 47(5):565–570, 1997.
50. Drénou B, Le Tulzo Y, Caulet-Maugendre S, et al: Pheochromocytoma and second- 83. Bergamaschi S, Giavoli C, Ferrante E, et al: Growth hormone replacement therapy in
ary erythrocytosis: Role of tumour erythropoietin secretion. Nouv Rev Fr Hematol growth hormone deficient children and adults: Effects on hemochrome. J Endocrinol
37(3):197–199, 1995. Invest 29(5):399–404, 2006.
51. Zhuang Z, Yang C, Lorenzo F, et al: Somatic HIF2A gain-of-function mutations in para- 84. Miniero R, Altomare F, Rubino M, et al: Effect of recombinant human growth hormone
ganglioma with polycythemia. N Engl J Med 367(10):922–930, 2012. (rhgh) on hemoglobin concentration in children with idiopathic growth hormone defi-
52. Yang C, Sun MG, Matro J, et al: Novel HIF2A mutations disrupt oxygen sensing, leading ciency-related anemia. J Pediatr Hematol Oncol 34(6):407–411, 2012.
to polycythemia, paragangliomas, and somatostatinomas. Blood 121(13):2563–2566, 85. Woody MA, Welniak LA, Sun R, et al: Prolactin exerts hematopoietic growth-promot-
2013. ing effects in vivo and partially counteracts myelosuppression by azidothymidine. Exp
53. Ladroue C, Carcenac R, Leporrier M, et al: PHD2 mutation and congenital erythrocy- Hematol 27(5):811–816, 1999.
tosis with paraganglioma. N Engl J Med 359(25):2685–2692, 2008. 86. Abkowitz JL, Schaison G, Boulad F, et al: Response of Diamond-Blackfan anemia to
54. Hawkins WW, Speck E, Leonard VG: Variation of the hemoglobin level with age and metoclopramide: Evidence for a role for prolactin in erythropoiesis. Blood 100(8):
sex. Blood 9(10):999–1007, 1954. 2687–2691, 2002.
55. Yeap BB, Beilin J, Shi Z, et al: Serum testosterone levels correlate with haemoglobin in 87. Socolovsky M, Dusanter-Fourt I, Lodish HF: The prolactin receptor and severely trun-
middle-aged and older men. Intern Med J 39(8):532–538, 2009. cated erythropoietin receptors support differentiation of erythroid progenitors. J Biol
56. Lewerin C, Nilsson-Ehle H, Jacobsson S, et al: Serum estradiol associates with blood Chem 272(22):14009–14012, 1997.
hemoglobin in elderly men: The MROS Sweden study. J Clin Endocrinol Metab 88. Socolovsky M, Fallon AE, Lodish HF: The prolactin receptor rescues EPOR−/−
99(7):2549–2556, 2014. erythroid progenitors and replaces EPOR in a synergistic interaction with c-kit. Blood
57. Fonseca R, Rajkumar SV, White WL, et al: Anemia after orchiectomy. Am J Hematol 92(5):1491–1496, 1998.
59(3):230–233, 1998. 89. Shimon I, Benbassat C, Tzvetov G, et al: Anemia in a cohort of men with macropro-
58. Bogdanos J, Karamanolakis D, Milathianakis C, et al: Combined androgen blockade- lactinomas: Increase in hemoglobin levels follows prolactin suppression. Pituitary
induced anemia in prostate cancer patients without bone involvement. Anticancer Res 14(1):11–15, 2011.
23(2C):1757–1762, 2003. 90. Iglesias P, Castro JC, Díez JJ: Clinical significance of anaemia associated with prolact-
59. Snyder PJ, Peachey H, Berlin JA, et al: Effects of testosterone replacement in hypogo- in-secreting pituitary tumours in men. Int J Clin Pract 65(6):669–673, 2011.
nadal men. J Clin Endocrinol Metab 85(8):2670–2677, 2000. 91. Ceccato F, Occhi G, Regazzo D, et al: Gonadotropin secreting pituitary adenoma
60. Calof OM, Singh AB, Lee ML, et al: Adverse events associated with testosterone associated with erythrocytosis: Case report and literature review. Hormones (Athens)
replacement in middle-aged and older men: A meta-analysis of randomized, placebo- 13(1):131–139, 2014.
controlled trials. J Gerontol A Biol Sci Med Sci 60(11):1451–1457, 2005. 92. Boxer M, Ellman L, Geller R, et al: Anemia in primary hyperparathyroidism. Arch
61. Fernández-Balsells MM, Murad MH, Lane M, et al: Clinical review 1: Adverse effects Intern Med 137(5):588–593, 1977.
of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin 93. Abarca J, Trigonis C, Hamberger B, et al: Anaemia in primary hyperparathyroidism—
Endocrinol Metab 95(6):2560–2575, 2010. fantasy or reality. Ann Chir Gynaecol 74(2):74–76, 1985.
62. Iyengar A, Sheppard D: A case of erythrocytosis in a patient treated with an aromatase 94. Bhadada SK, Bhansali A, Ahluwalia J, et al: Anaemia and marrow fibrosis in patients
inhibitor for breast cancer. Case Rep Hematol 2013:615189, 2013. with primary hyperparathyroidism before and after curative parathyroidectomy. Clin
63. Bachman E, Travison TG, Basaria S, et al: Testosterone induces erythrocytosis via Endocrinol (Oxf) 70(4):527–532, 2009.
increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/ 95. Argilés A, Mourad G, Lorho R, et al: Medical treatment of severe hyperparathyroid-
hemoglobin set point. J Gerontol A Biol Sci Med Sci 69(6):725–735, 2014. ism and its influence on anaemia in end-stage renal failure. Nephrol Dial Transplant
64. Beran M, Spitzer G, Verma DS: Testosterone and synthetic and androgens improve the 9(12):1809–1812, 1994.
in vitro survival of human marrow progenitor cells in serum-free suspension cultures. 96. Trunzo JA, McHenry CR, Schulak JA, et al: Effect of parathyroidectomy on anemia and
J Lab Clin Med 99(2):247–253, 1982. erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
65. Mantalaris A, Panoskaltsis N, Sakai Y, et al: Localization of androgen receptor expres- Surgery 144(6):915–918; discussion 919, 2008.
sion in human bone marrow. J Pathol 193(3):361–366, 2001. 97. Battistella M, Richardson RMA, Bargman JM, et al: Improved parathyroid hormone
66. Dukes PP, Goldwasser E: Inhibition of erythropoiesis by estrogens. Endocrinology control by cinacalcet is associated with reduction in darbepoetin requirement in
69:21–29, 1961. patients with end-stage renal disease. Clin Nephrol 76(2):99–103, 2011.
67. Piliero SJ, Medici PT, Haber C: The interrelationships of the endocrine and erythropoi- 98. Oshiro Y, Tanaka H, Okimoto N: A patient undergoing chronic dialysis whose renal
etic systems in the rat with special reference to the mechanism of action of estradiol and anemia was successfully corrected by treatment with cinacalcet. Clin Exp Nephrol
testosterone. Ann N Y Acad Sci 149(1):336–355, 1968. 15(4):607–610, 2011.

Kaushansky_chapter 38_p0559-0562.indd 562 9/17/15 6:19 PM